Inhalation preparation in treatment of tuberculosis

FIELD: medicine, phthisiology, pharmacy.

SUBSTANCE: invention proposes the inhalation preparation in treatment of tuberculosis comprising an antibacterial medicinal agent an aqueous solution. The preparation comprises also a medicinal preparation with the immunomodulating effect as 5-amino-2,3-dihydro-1,4-phthalazinedione potassium salt or 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt, or 5-amino-2,3-dihydro-1,4-phthalazinedione potassium and sodium salts taken in the equal ratio in the following ratio of components, wt.-%: antibacterial medicinal agent, 1.0-10.0; 5-amino-2,3-dihydro-1,4-phthalazinedione potassium salt or 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt, or 5-amino-2,3-dihydro-1,4-phthalazinedione potassium and sodium salts taken in the equal ratio, 1.0-10.0; water, the balance. The preparation inhibits activity of macrophages reducing the level of tumor necrosis factor (TNF) and acute-phase proteins that results to weakening intoxication symptoms, activates superoxide-forming function and phagocyte activity of neutrophile granulocytes, enhances the microbiocide system of cells that, in turn, results to arresting the inflammation process. Invention can be used as the inhalation agent in treatment of tuberculosis.

EFFECT: valuable medicinal properties of preparation.

2 cl, 2 ex

 

The invention relates to medicine and can be used in the treatment of infectious diseases caused by ingestion of the patient tubercle bacilli.

Well-known drug for inhalation containing 10% aqueous solution of isoniazid (see, for example, PPM Mashkovsky "drugs", Ed. "Medicine", M, 1985, Vol.2, s).

The drug has an effective impact in the treatment of pulmonary tuberculosis patients, however, with a long reception due to addiction to the drug and its replacement is necessary.

The closest analogue prototype is the drug for inhalation containing 5% aqueous solution of calutide soluble (see, for example, Medmaravis "drugs". Ed. "Medicine", M, 1985, so 2, C-318).

This drug is effective in the treatment of patients with different forms of tuberculosis, however, with a long reception due to addiction to the drug also need replacing.

The present invention solves the problem of obtaining a medicinal product for inhalation for the treatment of tuberculosis, ensuring the effectiveness of the treatment.

The essence of the invention lies in the fact that the drug for inhalation for the treatment of tuberculosis, containing an aqueous solution of antibacterial drugs, includes drug immunomoduliruushimi steps in the de or potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or a mixture in equal proportions of potassium and sodium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione, in the following ratio of components, wt.%: antibacterial drug - 1,0-10,0; potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or a mixture in equal proportions of potassium and sodium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione - 1,0-10,0; water - the rest.

At the same time as antibacterial drug use salyuzid soluble.

Studies have shown that the use of the proposed drug for inhalation for the treatment of tuberculosis due to the bifurcation of the activity contained in the product immunomodulator in view of the above-mentioned salts of 5-amino-2,3-dihydro-1,4-phthalazinedione or their mixtures in inflammatory processes selectively for a few hours inhibits the activity of macrophages, reducing accordingly the level of TNF and ostrofsky proteins, which leads to smoothing of the symptoms of intoxication. When this happens enhanced superoxidedismutase function and phagocytic activity of neutrophils and the corresponding strengthening of microbicide system cells and the relief of the inflammatory process.

When the weak response of cellular immunodeficiency is itata offer medication ensures the release of TNF (tumor necrosis factor), interleukins and other ostrofsky proteins, indicating that the activation of macrophages. At the same time also specifically react to the introduction of a drug T-lymphocytes.

Studies have shown that entered the patient the drug in the form of alkali (for example, sodium, or potassium) salt of 5-amino-2,3-dihydro-1,4-phthalazinedione (chemical formula, respectively, or C8H6N3O2Na, or8H6N3AboutCK) or mixtures of these alkaline salts. This salt (mixture of salts) is divided into metal cations (respectively Na+or+) and anions 5-amino-3-hydro-1,4-phthalazinedione (respectively, C8H6N3O2-). However cations fill the needs of the body, and anions interacting, for example, blood plasma, disintegrate emitting carbon, atomic oxygen, nitrogen and hydroxyl group (OH). Then oxygen and nitrogen are recovered, thereby setting the antioxidant activity and hydroxyl groups interact with carbon, translating KHS from a state of acidosis in the alkaline side.

In addition, due to the presence of the chemiluminescent properties lyuminola on the basis of which formed the drug, under oxidative reactions with lyuminola (with the anion of 5-amino-3-hydro-1,4-nafta is aindiana) is the emission of light energy (see also, for example, http://www.gpo.ucop.edu, Briheim et al., 1984), and in the interaction with albumin increased intensity of chemiluminescence proportional to the increase in the concentration of albumin (see ibid., Buturiakin et al., 1975).

Studies have shown that the emission of light energy by chemiluminescence is perceived by the cells of the body, and the emitted when the quanta of light energy are involved in the mechanism of exchange as contributing to the process of exchange of energy supply.

Studies have also shown that in the case of a changed state of the membrane (cytoplasm) of the cell introduction drug alkali metal salts or mixtures of these salts lyuminola causes the membrane in the normal state, normalizes and regulates inside and intercellular metabolic processes and therefore normalizes metabolism.

It follows from the above that the introduction of the patient along with complex antibacterial drugs mentioned alkali metal salts or a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione restores and stabilizes the immune status of the patient.

The results of applying the proposed drug for inhalation for the treatment of tuberculosis has shown its effectiveness and reducing treatment time.

The invention is confirmed by the examples.

<> Example 1.

Patient E., 42.

Complaints on frequent bouts of prolonged dry cough, constant fatigue.

Two years before treatment were receiving TB treatment at the hospital.

Turning: RG darkening in the upper lobe of the left lung, skin test positive.

From admission refused.

A course of treatment by inhalation using the drug:

First, within 2 weeks, every day, 3-4 times a day and before bedtime inhalation drug product containing the following ratio of components, wt.%: salyuzid - 10,0; a mixture in equal proportions of potassium and sodium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione - 10,0; water - the rest.

Two weeks later, the tone has improved, the coughing has almost stopped after the procedure inhalation may experience intermittent cough.

In the next two weeks under the old scheme inhalation day - drug containing the following ratio of components, wt.%: salyuzid - 5,0; sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione - 10,0; water - the rest, and before bedtime medicinal preparation containing the following ratio of components, wt.%: salyuzid - 5,0; potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione - 5,0; water - the rest.

After the course - satisfactory, n is fluorochrome - traces of burning in left lung.

Recommended 2-3 months to continue conducting preventive inhalation 1-2 times daily drug, containing the following ratio of components, wt.%: salyuzid - 1,0; sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione - 1,0; water - the rest and bedtime is a pharmaceutical preparation containing the following ratio of components, wt.%: salyuzid - 1,0; potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione - 1,0; water - the rest.

Six months later the patient from previously assigned survey refused, citing on the phone in the normal state and the virtual cessation of coughing.

Example 2.

Patient T., 29 years.

When handling complaints exhausting cough, fever, depression.

Six months before treatment were receiving inpatient treatment of tuberculosis.

During the examination tuberculin skin test positive.

Diagnosis: postwarranty residual effects.

Completed the treatment with periodic examination of the patient every week.

First, within 2 weeks, every day, 3-4 times a day and before bedtime conducted inhalation drug product containing the following ratio of components, wt.%: salyuzid - 10,0; a mixture in equal proportions of potassium and sodium salts of 5-amino-2,3-dihyd the on-1,4-phthalazinedione - 10,0; water - the rest.

Two weeks later observed periodic cough after each inhalation, the tone was slightly increased.

Then within two weeks was continued conducting inhalation: day 2-3 times a medicinal preparation containing the following ratio of components, wt.%: salyuzid - 5,0; a mixture in equal proportions of potassium and sodium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione - 10,0; water - the rest, and before bedtime is a pharmaceutical preparation containing the following ratio of components, wt.%: salyuzid - 5,0; potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione - 10,0; water - the rest.

When examining the dynamics is positive.

Over the next two weeks inhalation according to the revised scheme: day - drug containing the following ratio of components, wt.%: salyuzid - 5,0; sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione - 10,0; water - the rest, and before bedtime medicinal preparation containing the following ratio of components, wt.%: salyuzid - 5,0; potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione - 10,0; water - the rest.

If the examination is satisfactory, the temperature is normalized, TST - negative.

Recommended within the next 2-3 months to continue preventive conduct inhale is s daily, 1-2 times daily drug, containing the following ratio of components, wt.%: salyuzid - 1,0; sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione - 1,0; water - the rest and bedtime is a pharmaceutical preparation containing the following ratio of components, wt.%: salyuzid - 1,0; potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione - 1,0; water - the rest.

Also recommended physical therapy sessions.

1. Drug for inhalation for the treatment of tuberculosis, containing an aqueous solution of antibacterial drugs, characterized in that it also includes drug immunomodulating action in the form or potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or a mixture in equal proportions of potassium and sodium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione, in the following ratio of components, wt.%: antibacterial drug 1,0-10,0; potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or a mixture in equal proportions of potassium and sodium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione 1,0-10,0; water the rest.

2. The preparation according to claim 1, characterized in that as an antibacterial drug use salyuzid soluble.



 

Same patents:

FIELD: medicine, rheumatology, pharmacy.

SUBSTANCE: invention proposes ointment as a curative agent that comprises the following components: 5-amino-2,3-dihydro-1,4-phthalazinedione alkaline salt of mixture of alkaline salts, medicinal vaseline, vaseline oil as an ointment base and distilled water taken in the following ratio of components, wt.-%: 5-amino-2,3-dihydro-1,4-phthalazinedione alkaline salt or 5-amino-2,3-dihydro-1,4-phthalazinedione mixture of alkaline salts, 1.0-50.0; medicinal vaseline, 10.0-20.0; vaseline oil, 5.0-10.0, and water, the balance, wherein 5-amino-2,3-dihydro-1,4-phthalazinedione sodium or potassium salt is used as an alkaline salt, and 5-amino-2,3-dihydro-1,4-phthalazinedione sodium and potassium salts mixture is used as mixture of alkaline salts composed of the equal ratio of components, i. e. 5-amino-2,3-dihydro-1,4-phthalazinedione sodium and potassium salts mixture. Indicated ointment normalizes membrane cell to the normal state damaged as result of disease, regulated intra- and intercellular metabolic processes that, in turn, promotes to normalization of metabolism and arresting inflammation for the shortest times. Invention can be used in treatment of autoimmune disease.

EFFECT: improved and valuable medicinal properties of ointment.

3 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new 6-alkyl-5-(2-isonicotinoylsulfohydrazoyl)uracil hydrochlorides of the general formula (I) wherein R means alkyl comprising 1-4 carbon atom. Compounds possess an anti-mycobacterial and an immunotropic activity and can be used as an immunomodulating agent and an anti-mycobacterial agents. Also, invention relates to a pharmaceutical composition based on thereof.

EFFECT: valuable medicinal properties of compounds.

4 cl, 10 tbl, 2 ex

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with cooling selected fertilized uninfected eggs at 2-4 C up to 7 d followed by homogenization, diluting with physiological solution of egg mass, bactericidal treatment, conservation with phenol solution up to its concentration being 0.3% at subsequent filtration of target product. Moreover, egg mass should be diluted with physiological solution at the ratio of 1:5, then comes thermal treatment upon water bath at 70-80 C for 1 h and before conservation one should cool the target product in bactericidal chamber under the lamp with ultraviolet irradiation for 30-40 min. The method provides increased total and specific body resistance, it enables to obtain cheaper and more acceptable biostimulant and simplified way for preparing.

EFFECT: higher efficiency.

4 ex, 3 tbl

FIELD: medicine, biopharmacology, immunology.

SUBSTANCE: invention relates to manufacturing curative-prophylactic preparations based on leukocyte interferon and natural cytokines. The preparation based on complex of natural cytokines is prepared by induction of human leukocytes with Newcastle disease virus of strain "H". Indicated complex of natural cytokines is prepared by at least two treatments of leukocytes before induction stage with virus with the same natural complex of cytokines prepared in previous stage of induction. Complex is purified from foreign proteins of inductor and comprises 104 IU of antiviral activity of human interferon-alpha in one ampoule, not less, and cellular cytokines, phosphate buffer for maintaining pH 6.9-7.5, sodium chloride and mannitol. The end product is lyophilized for preparing the injection preparation. Invention provides increasing activity of the preparation and to retain the natural complex of cytokines.

EFFECT: improved preparing method, valuable medicinal properties of preparation.

3 cl, 2 ex

FIELD: medicine, gastroenterology, pharmacy.

SUBSTANCE: invention relates to agents used in treatment of ulcerous-erosion injures in gastroduodenal region. Method involves diluting 100 mcg of dry lyophilized powder of immunomodulating agent "Superlimf" in 3-5 ml of 0.9% isotonic solution and irrigation of ulcer or erosion with this solution 1 time per a day by the endoscopy method. The treatment course is 3-4 procedures with break for 4-5 days. Method provides alteration of cytokine pattern of tissues, induction of influx of mononuclear phagocytes to the injure focus that results to localization of inflammation and the complete epithelization of ulcers and erosions.

EFFECT: improved and effective method for treatment.

1 ex

FIELD: medicine, pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to a method for preparing an anti-inflammatory, wound-healing, capillary-strengthening, immunomodulating agent. Method for preparing an anti-inflammatory, wound-healing, capillary-strengthening, immunomodulating agent is carried out for four stages. At the first stage violet tricolor and/or field milled herb is extracted with fluidized carbon dioxide under the definite condition followed by separation of grist from lipophilic fraction of extract; at the second stage defatted grist is subjected for three-fold extraction by remaceration method under the definite condition followed by treatment and purification of combined extract, treatment, condensation and preparing liquid alcoholic extract; at the third stage liquid alcoholic extract is used for preparing polysaccharide and flavonoid complexes by precipitation of polysaccharide with three-fold volume of 96% ethyl alcohol and the following drying at the definite temperature; at the forth stage grist after isolation of polysaccharide and flavonoid complexes is used for preparing pectins by treatment with three-fold volume of ammonium oxalate solution at the definite temperature, evaporation and drying. Liquid alcoholic is evaporated to 1/5 of the parent volume, dried by spraying drying or lyophilic drying at definite temperatures. Each end product prepared at each stage can be used as both independent medicinal formulation and can be used for preparing other medicinal formulations (tablets, capsules, suppositories, films). Also, invention relates to a method for preparing an anti-inflammatory, wound-healing, capillary-strengthening, immunomodulating agent that involves extraction of violet tricolor and/or field milled herb with 70% ethyl alcohol by infusion for a definite time followed by purification of the end product, settling at the definite temperature and filtration. Method provides preparing agent with broad pharmacological pattern of action and provides the maximal using the medicinal vegetable raw.

EFFECT: improved preparing method, valuable medicinal properties of agent.

5 cl, 5 tbl, 17 ex

FIELD: medicine.

SUBSTANCE: means has lipid fraction obtained from Berryteuthis Magister Comandor squid liver containing 10% of polyunsaturated fatty acids and 50% of alkyl-diacylglycerides showing marked lipid-correcting and immunomodulating properties.

EFFECT: enhanced effectiveness in treating lipid metabolism disorders and immunity system disorders.

4 tbl

FIELD: medicine.

SUBSTANCE: method involves administering inmmunotherapy with recombinant interferon-α2b in daily dose of 3x106 MU. It is incubated in thermostat during 1 h at 37°C with 100 ml of autoblood and then it is intravenously introduced to a patient during 1-1.5h daily under blood formula control to reach leukocyte content of>4*109 /l, granulocytes >2*109 /l.

EFFECT: eliminated leukopenia and dose-limiting toxicity risk; accelerated treatment course; reduced risk of infectious complications.

FIELD: agriculture, veterinary science.

SUBSTANCE: during the 1st d after forming raising groups one should once inject intramuscularly a solution of "Complex A" preparation at the dosage of 0.30-0.32 mg/kg body weight for 45-60-d-aged piglets and simultaneously with fodder one should introduce "Lactobifadol" preparation at the quantity of 0.50-0.52 g/kg body weight during the first 1-5 d. The present innovation enables to activate immune system, increase total protein and hemoglobin in blood that in its turn, prevents bronchopneumonia and remove stress in piglets after forming special raising groups.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

FIELD: medicine, ophthalmology.

SUBSTANCE: as an immunomodulating remedy one should introduce tamerite per 0.5 ml subconjunctivally and per 1.5 ml i/m daily for 5 d. The method provides normalization of immunity values due to additional local complex manifestation of immunomodulating, antiphlogistic, antioxidant and regenerating effects of tamerite.

EFFECT: higher efficiency of complex therapy.

2 ex

FIELD: medicine.

SUBSTANCE: one should perform the following stages: a) removal of contaminants out of plant; b) plant's reducing; c) treatment of reduced plant with laser radiation; d) suspending the mixture obtained at stage c) in water; e) maceration of suspension obtained at stage d) and f) separation of liquid developed. Composition should be obtained due to this technique. It should be applied at treating hepatitis C as an aqueous extract. It should be applied as aqueous extract as immunostimulant. Pharmaceutical preparation includes aqueous extract as an active constituent.

EFFECT: increased biological activity of the product.

43 cl, 16 ex, 1 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new 6-alkyl-5-(2-isonicotinoylsulfohydrazoyl)uracil hydrochlorides of the general formula (I) wherein R means alkyl comprising 1-4 carbon atom. Compounds possess an anti-mycobacterial and an immunotropic activity and can be used as an immunomodulating agent and an anti-mycobacterial agents. Also, invention relates to a pharmaceutical composition based on thereof.

EFFECT: valuable medicinal properties of compounds.

4 cl, 10 tbl, 2 ex

FIELD: medicine, phthisiology, pharmaceutical industry.

SUBSTANCE: invention relates to applying betulin as an agent used in treatment and prophylaxis of tuberculosis, in particular, to applying birch bark as an agent for treatment and prophylaxis of tuberculosis in the content of betulin in birch bark extract above 70%. Betulin and birch bark extract promote to effective treatment and prophylaxis of tuberculosis. Invention can be used in treatment and prophylaxis of tuberculosis.

EFFECT: valuable medicinal properties of agent.

3 cl, 15 tbl, 6 dwg

FIELD: medicine, phthisiology.

SUBSTANCE: method involves administration of roncoleukin by lymphotropic route: subcutaneously, in region of pretracheal cellular tissue in the equal dose 1/4-1/5 of the average daily therapeutic dose, once in one or two days, 3 injections for a course. Invention provides the local delivery of roncoleukin to the injure zone directly that promotes to making depot of the latter in the injure focus and to the rapid elimination of pathogen from body of patients. Invention can be used for correction of immune insufficiency in patients with pulmonary tuberculosis.

EFFECT: improved method for correction.

2 ex

FIELD: medicine, phthisiology.

SUBSTANCE: additionally to chemotherapy including combination of antituberculous preparations based upon isoniazide or isoniazide and rifampicin one should prescribe zinc sulfate at daily dosage being 2.30-35 mg/kg due to twice or thrice oral intake during 21-28 d. The present innovation enables to shorten period of chemotherapy due to taking antilogarithms for the action of chemopreparations with zinc sulfate.

EFFECT: higher efficiency of therapy.

6 ex

FIELD: medicine.

SUBSTANCE: method involves rectally introducing mixture produced on base of 5% Novocain solution containing isoniazid, rifamycin, ethambutol in therapeutic doses daily during 21 days. The mixture is pretreated in ultrasonic field during 5 min at 2 MHz frequency.

EFFECT: improved bacteriostatic blood and prostate secret activity.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: the suggested composition includes therapeutically efficient quantity of para-aminosalicylic acid (PASA) as an active substance and target additives as sorbitol, polyvinyl pyrrolidone, salt of stearic acid, talc and citric acid. Pharmaceutical composition is designed as tablets covered with a membrane. The latter contains either "Acryl-iz" of Calarcon firm or composition consisting of copolymer of methacrylic acid with ethylacrylate, titanium dioxide, talc, propylene glycol and iron oxide. The suggested PASA-based antitubercular preparation meets all normative requirements of the State Pharmacopoeia, XI publication and has expiry terms of 2 yr.

EFFECT: higher efficiency of application.

6 cl, 3 ex, 1 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a medicinal agent made as a gelatin capsule. A medicinal agent as gelatin capsule consists of cycloserine and accessory additives wherein calcium phosphate dihydrate, aerosil and calcium stearate taken in the definite components are used as accessory additives. Also, gelatin capsule comprises additionally glutamic acid, gelatin and water, Invention provides rapid and complete release of agent in intake and the development of a medicinal formulation reducing toxicity of an active substance and eliciting stability in storage.

EFFECT: improved and valuable pharmaceutical and medicinal properties of agent.

1 tbl, 1 ex

FIELD: pharmaceutical industry.

SUBSTANCE: invention provides antituberculous formulation made in the form of solid dosage form containing as active principle combination of isoniazid, rifampicin, pyrazinamide, ethambutol hydrochloride, and pyridoxine hydrochloride plus pharmaceutically acceptable auxiliaries: starch, lubricant, and optionally microcrystalline cellulose. Composition is characterized by storage stability and high therapeutical efficiency.

EFFECT: increased assortment of antituberculous drugs.

6 cl, 2 tbl, 3 ex

FIELD: pharmaceutical industry.

SUBSTANCE: invention provides high-activity antituberculous formulation made in the form of solid dosage form containing as active principle combination of lomefloxacin, protionamide, pyrazinamide, ethambutol hydrochloride, and pyridoxine hydrochloride plus pharmaceutically acceptable auxiliaries.

EFFECT: increased assortment of antituberculous drugs.

4 cl, 1 tbl, 4 ex

FIELD: medicine, rheumatology, pharmacy.

SUBSTANCE: invention proposes ointment as a curative agent that comprises the following components: 5-amino-2,3-dihydro-1,4-phthalazinedione alkaline salt of mixture of alkaline salts, medicinal vaseline, vaseline oil as an ointment base and distilled water taken in the following ratio of components, wt.-%: 5-amino-2,3-dihydro-1,4-phthalazinedione alkaline salt or 5-amino-2,3-dihydro-1,4-phthalazinedione mixture of alkaline salts, 1.0-50.0; medicinal vaseline, 10.0-20.0; vaseline oil, 5.0-10.0, and water, the balance, wherein 5-amino-2,3-dihydro-1,4-phthalazinedione sodium or potassium salt is used as an alkaline salt, and 5-amino-2,3-dihydro-1,4-phthalazinedione sodium and potassium salts mixture is used as mixture of alkaline salts composed of the equal ratio of components, i. e. 5-amino-2,3-dihydro-1,4-phthalazinedione sodium and potassium salts mixture. Indicated ointment normalizes membrane cell to the normal state damaged as result of disease, regulated intra- and intercellular metabolic processes that, in turn, promotes to normalization of metabolism and arresting inflammation for the shortest times. Invention can be used in treatment of autoimmune disease.

EFFECT: improved and valuable medicinal properties of ointment.

3 ex

Up!